Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Amortization of Deferred Charges: 2015-2020

Historic Amortization of Deferred Charges for Outlook Therapeutics (OTLK) over the last 5 years, with Jun 2020 value amounting to $99,849.

  • Outlook Therapeutics' Amortization of Deferred Charges fell 76.17% to $99,849 in Q2 2020 from the same period last year, while for Jun 2020 it was $654,702, marking a year-over-year decrease of 54.21%. This contributed to the annual value of $2.7 million for FY2024, which is 6.01% up from last year.
  • According to the latest figures from Q2 2020, Outlook Therapeutics' Amortization of Deferred Charges is $99,849, which was down 16.84% from $120,065 recorded in Q1 2020.
  • In the past 5 years, Outlook Therapeutics' Amortization of Deferred Charges registered a high of $1.7 million during Q3 2017, and its lowest value of $2,504 during Q2 2016.
  • In the last 3 years, Outlook Therapeutics' Amortization of Deferred Charges had a median value of $230,217 in 2018 and averaged $254,026.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first skyrocketed by 53,110.98% in 2017, then tumbled by 96.51% in 2019.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Amortization of Deferred Charges stood at $140,820 in 2016, then skyrocketed by 311.58% to $579,586 in 2017, then declined by 22.29% to $450,381 in 2018, then crashed by 96.51% to $15,722 in 2019, then crashed by 76.17% to $99,849 in 2020.
  • Its Amortization of Deferred Charges stands at $99,849 for Q2 2020, versus $120,065 for Q1 2020 and $15,722 for Q4 2019.